表紙
市場調査レポート

糖尿病性黄斑浮腫:パイプライン製品の分析

Diabetic Macular Edema - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213121
出版日 ページ情報 英文 192 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
糖尿病性黄斑浮腫:パイプライン製品の分析 Diabetic Macular Edema - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 192 Pages
概要

糖尿病性黄斑浮腫(DME)は、糖尿病患者の網膜の血管が傷害されて血液中の水分や脂肪が漏れ出し、物を見る中心部の黄斑部にむくみが生じた状態(黄斑浮腫)をいいます。視界不良、飛蚊症、複視といった症状が見られ、未治療の場合は失明に至ります。素因は、年齢と糖尿病です。

当レポートでは、糖尿病性黄斑浮腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

糖尿病性黄斑浮腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • F. Hoffmann-La Roche Ltd.
  • Allergan, Inc.
  • pSivida Corp.
  • GlaxoSmithKline plc
  • Quark Pharmaceuticals, Inc.
  • 参天製薬
  • Astellas Pharma Inc.
  • 興和
  • Pfizer Inc.
  • Genmab A/S
  • TheraKine Ltd.
  • iCo Therapeutics Inc.
  • NicOx S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Handok Inc.
  • ThromboGenics NV
  • Foamix Ltd.
  • Acucela Inc.
  • 千寿製薬
  • Molecular Design International, Inc.
  • Pfenex Inc.
  • Icon Bioscience, Inc.
  • Eleven Biotherapeutics
  • Ampio Pharmaceuticals, Inc.
  • ActiveSite Pharmaceuticals, Inc.
  • AlphaMab Co., Ltd

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • dexamethasone acetate
  • aflibercept
  • fluocinolone acetonide
  • aflibercept
  • DMI-5207
  • betamethasone
  • darapladib
  • iCo-007
  • ocriplasmin
  • ripasudil
  • PF-655
  • MP-0112
  • AKB-9778
  • difluprednate
  • PF-04634817
  • 49-B
  • dexamethasone dipropionate
  • KH-902
  • ALG-1001
  • fluticasone propionate
  • ranibizumab
  • emixustat hydrochloride
  • teprotumumab
  • nesvacumab
  • Drug For Diabetic Macular Edema
  • NCX-434
  • ASP-440
  • NCX-422
  • AVA-101
  • ranibizumab biosimilar
  • Plasma Kallikrein Inhibitors Programme
  • EBI-018
  • Small Molecule to Inhibit VAP-1 for Diabetic Macular Edema
  • EBI-029
  • Plasma Kallikrein Inhibitors Programme
  • OPK-20018
  • ranibizumab biosimilar
  • Protein Therapeutic For Diabetic Macular Edema
  • Peptide For Diabetic Macular Edema
  • HL-5511
  • minocycline Gel

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7647IDB

Summary

Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2016', provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Macular Edema Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Macular Edema - Overview
    • Pipeline Products for Diabetic Macular Edema - Comparative Analysis
  • Diabetic Macular Edema - Therapeutics under Development by Companies
  • Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Macular Edema - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Diabetic Macular Edema - Products under Development by Companies
  • Diabetic Macular Edema - Products under Investigation by Universities/Institutes
  • Diabetic Macular Edema - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • ActiveSite Pharmaceuticals, Inc.
    • Acucela Inc.
    • Aerpio Therapeutics, Inc.
    • Allergan Plc
    • Ampio Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Avalanche Biotechnologies, Inc.
    • Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
    • Chong Kun Dang Pharmaceutical Corp.
    • EyeGate Pharmaceuticals, Inc.
    • EyeGene, Inc.
    • Gene Signal International SA
    • Genmab A/S
    • Icon Bioscience, Inc.
    • Kala Pharmaceuticals, Inc.
    • Kowa Company, Ltd.
    • Mabion SA
    • MacuCLEAR, Inc.
    • NicOx S.A.
    • Oculis ehf
    • Ohr Pharmaceutical Inc.
    • Quark Pharmaceuticals, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • SciFluor Life Sciences, LLC
    • Senju Pharmaceutical Co., Ltd.
    • Shire Plc
    • Sucampo Pharmaceuticals, Inc.
    • ThromboGenics NV
    • Verseon Corporation
    • Xbrane Biopharma AB
  • Diabetic Macular Edema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aflibercept + nesvacumab) - Drug Profile
    • abicipar pegol - Drug Profile
    • ACX-107 - Drug Profile
    • aganirsen - Drug Profile
    • AKB-9778 - Drug Profile
    • ALG-1001 - Drug Profile
    • Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile
    • ASP-440 - Drug Profile
    • ASP-8232 - Drug Profile
    • ASPPDC-010 - Drug Profile
    • AVA-101 - Drug Profile
    • conbercept - Drug Profile
    • danazol - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone dipropionate - Drug Profile
    • dexamethasone dipropionate XR - Drug Profile
    • difluprednate - Drug Profile
    • Drug for Diabetic Macular Edema - Drug Profile
    • Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile
    • EG-Mirotin - Drug Profile
    • emixustat hydrochloride - Drug Profile
    • fluticasone propionate - Drug Profile
    • JDE-006 - Drug Profile
    • KVD-001 - Drug Profile
    • lanadelumab - Drug Profile
    • loteprednol etabonate - Drug Profile
    • MC-4001 - Drug Profile
    • methotrexate - Drug Profile
    • MTP-131 - Drug Profile
    • NCX-422 - Drug Profile
    • NCX-434 - Drug Profile
    • nesvacumab - Drug Profile
    • NM-108 - Drug Profile
    • OLX-303 - Drug Profile
    • PF-655 - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • RC-1 Alpha - Drug Profile
    • ripasudil - Drug Profile
    • RTU-1096 - Drug Profile
    • RX-10045 - Drug Profile
    • SF-0166 - Drug Profile
    • Small Molecule for Diabetic Macular Edema - Drug Profile
    • Small Molecule to Inhibit Kallikrein for DME - Drug Profile
    • Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile
    • squalamine lactate - Drug Profile
    • teprotumumab - Drug Profile
    • TG-758 - Drug Profile
    • TG-931 - Drug Profile
    • triamcinolone acetonide - Drug Profile
  • Diabetic Macular Edema - Recent Pipeline Updates
  • Diabetic Macular Edema - Dormant Projects
  • Diabetic Macular Edema - Discontinued Products
  • Diabetic Macular Edema - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Macular Edema, H1 2016
  • Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Diabetic Macular Edema - Pipeline by Aciont Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2016
  • Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H1 2016
  • Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by EyeGene, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2016
  • Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2016
  • Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2016
  • Diabetic Macular Edema - Pipeline by Mabion SA, H1 2016
  • Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by NicOx S.A., H1 2016
  • Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2016
  • Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H1 2016
  • Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016
  • Diabetic Macular Edema - Pipeline by Shire Plc, H1 2016
  • Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2016
  • Diabetic Macular Edema - Pipeline by Verseon Corporation, H1 2016
  • Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H1 2016
  • Diabetic Macular Edema - Dormant Projects, H1 2016
  • Diabetic Macular Edema - Dormant Projects (Contd..1), H1 2016
  • Diabetic Macular Edema - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Diabetic Macular Edema, H1 2016
  • Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top